Cargando…

Skin tattooing as an effective tool for delivering DNA and protein vaccine immunogens

Detalles Bibliográficos
Autores principales:	Chiu, Y, Jiang, X, Kumar, R, Hioe, CE, Zolla-Pazner, S, Kong, X
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3441817/ http://dx.doi.org/10.1186/1742-4690-9-S2-P338

Ejemplares similares

P04-55 LB. Anti-V3 monoclonal antibodies display broad neutralizing activities against multiple HIV-1 subtypes
por: Zolla-Pazner, S, et al.
Publicado: (2009)

P04-09. Induction of cross-clade neutralizing antibodies with a prime/boost vaccine strategy focused on a neutralizing epitope
por: Zolla-Pazner, S, et al.
Publicado: (2009)

P12-13. Structure-guided design and immunological characterization of immunogen constructs presenting the HIV-1 gp120 V3 loop on a CTB scaffold
por: Totrov, M, et al.
Publicado: (2009)

Fusion of CTA and CTB gene to immunogen significantly enhances the immunogenicity of DNA vaccine
por: Ren, X, et al.
Publicado: (2012)

P19-21. Sequence variability in the crown of the V3 loop of the HIV-1 envelope is clustered within a small 3D structural zone
por: Almond, D, et al.
Publicado: (2009)

High-resolution crystal structure of the Fv of quaternary neutralizing epitope mAb 2909 reveals atomic details of its antigen-binding site
por: Sampson, JM, et al.
Publicado: (2012)

Improving immunogenicity of HIV-1 envelope gp120 by glycan removal and immune complex formation
por: Kumar, R, et al.
Publicado: (2012)

Crystal structure analysis of anti-V2 mAb 2158 suggests a conformational epitope involving an N-linked glycan
por: Spurrier, B, et al.
Publicado: (2012)

Biophysical dissection of the antigen-antibody interaction of the broadly reactive anti-V3 human mAb 447-52D
por: Killikelly, A, et al.
Publicado: (2012)

P20-09. Worldwide epitope prevalence of crystallographically resolved anti-V3 antibodies
por: Swetnam, J, et al.
Publicado: (2009)

Residue 315 regulates V3 exposure and V3 antibody recognition on HIV subtype B and C viruses
por: Manhas, S, et al.
Publicado: (2012)

P04-42. Molecular design of a mimotope that preserves conserved structural elements of the HIV-1 V3 crown
por: Jiang, X, et al.
Publicado: (2009)

Antigenicity and immunogenicity of a novel, acute HIV-1 Tanzanian subtype C gp145 envelope protein for clinical development
por: Polonis, V, et al.
Publicado: (2012)

P05-03. The use of immune complexes to enhance antibody responses against neutralizing epitopes on HIV envelope
por: Hioe, CE, et al.
Publicado: (2009)

Breadth or conservation score (CS): which is more important for HIV-1 T cell based vaccine immunogen design?
por: Kunwar, P, et al.
Publicado: (2012)

A novel rabbit monoclonal antibody platform to dissect the diverse repertoire of antibody epitopes for HIV-1 Env immunogen design
por: Chen, Y, et al.
Publicado: (2012)

The efficiency of bridging sheet recruitment determines HIV-1 R5 envelope sensitivity to soluble CD4 and macrophage tropism
por: O'Connell, O, et al.
Publicado: (2012)

P14-10. Comparable immunogenicity of VRC DNA and rAd5 HIV-1 vaccines delivered by intramuscular, subcutaneous and intradermal routes in healthy adults (VRC 011)
por: Ledgerwood, JE, et al.
Publicado: (2009)

P07-03. HIV gp120 interaction with CD4+ T cells induces local intracellular signaling and creates an F-actin depleted zone in the virological synapse
por: Vasiliver-Shamis, G, et al.
Publicado: (2009)

P02-08. Enhancement of HIV-1 DNA vaccine immunogenicity by BCG-PSN, a novel adjuvant
por: Sun, J, et al.
Publicado: (2009)

P19-17. Construction of HIV-1 AE subtype gp140 DNA vaccine and immunogenicity evaluation
por: Zhang, C, et al.
Publicado: (2009)

Development of chimeric HIV Env immunogens for mucosal delivery with attenuated canine distemper virus (CDV) vaccine vectors
por: Zhang, X, et al.
Publicado: (2012)

P04-10. Neutralization of Tier 1 and Tier 2 pseudoviruses by human anti-V3 monoclonal antibodies
por: Gorny, MK, et al.
Publicado: (2009)

A novel intradermal tattoo-based injection device enhances the immunogenicity of plasmid DNA vaccines
por: Gomez, Alejandro M., et al.
Publicado: (2022)

Enhanced immunogenicity of a nanoparticle therapeutic cancer vaccine targeting HAAH delivered intradermally using 3M's hollow microstructured transdermal system (hMTS)
por: Fuller, Steven, et al.
Publicado: (2015)

P14-15 LB. The safety and immunogenicity of HIV-1 vaccines based on DNA and replication competent vaccinia vector in phase I clinical trial
por: Shao, Y, et al.
Publicado: (2009)

Detection of antibodies to the α4β7 integrin binding site on HIV-1 gp120 V2 loop using a novel cell adhesion assay
por: Rao, M, et al.
Publicado: (2012)

P19-01. Pre-clinical immunogenicity of mosaic Asian AE/B HIV-1 DNA vaccine in mice
por: Sirivichayakul, S, et al.
Publicado: (2009)

DNA plasmid HIV vaccine design, number of doses, participant gender, and body mass index affect T-cell responses across HIV vaccine clinical trials
por: Morgan, C, et al.
Publicado: (2012)

P04-07. Guiding the immune system through complex maturation pathways: a novel multi-immunogen approach for elicitation of broadly neutralizing antibodies
por: Xiao, X, et al.
Publicado: (2009)

P19-58 LB. Comparison of the immunogenicity in humans and rhesus macaques of vaccines consisting of DNA priming and MVA boosting and MVA priming and boosting
por: Robinson, HL, et al.
Publicado: (2009)

Tattoo-induced psoriasis
por: Orzan, OA, et al.
Publicado: (2014)

Do circulating HIV vaccine plasmids contribute to immunogenicity in humans?
por: Wahren, B, et al.
Publicado: (2006)

P16-36. Functional genomic immune profile of SIV DNA vaccines delivered by electroporation and combined with molecular adjuvants
por: Boyer, JD, et al.
Publicado: (2009)

Viral vector delivery of Env trimer immunogens
por: Parks, CL, et al.
Publicado: (2012)

Rationally Targeted Mutations at the V1V2 Domain of the HIV-1 Envelope to Augment Virus Neutralization by Anti-V1V2 Monoclonal Antibodies
por: Shen, Guomiao, et al.
Publicado: (2015)

Immunogenicity of a universal HIV-1 vaccine vectored by DNA, MVA and CHADV-63 in a Phase I/IIA clinical trial
por: Borthwick, NJ, et al.
Publicado: (2012)

Stable HIV-1 envelope glycoprotein immune complexes as vaccine immunogens
por: van Montfort, Thijs, et al.
Publicado: (2011)

Immunogenic selection of HIV-1 MPER epitopes for improved vaccine design
por: Wieczorek, L, et al.
Publicado: (2012)

Phase I clinical trials of safety and immunogenicity of live cultural influenza vaccine vector-flu
por: Nechaeva, Elena A, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_g2f85dlqqe0f6rio00hviv4jd7